Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
Guizhou Xinbang Pharmaceutical Co Ltd
Interest Income Expense
Guizhou Xinbang Pharmaceutical Co Ltd
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
|
Interest Income Expense
-¥12.1m
|
CAGR 3-Years
54%
|
CAGR 5-Years
37%
|
CAGR 10-Years
-1%
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Interest Income Expense
¥1.1B
|
CAGR 3-Years
52%
|
CAGR 5-Years
82%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Interest Income Expense
¥134.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
23%
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Interest Income Expense
¥429.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
30%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Interest Income Expense
¥1.1B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
37%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Interest Income Expense
-¥20.1m
|
CAGR 3-Years
-107%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Guizhou Xinbang Pharmaceutical Co Ltd's Interest Income Expense?
Interest Income Expense
-12.1m
CNY
Based on the financial report for Mar 31, 2024, Guizhou Xinbang Pharmaceutical Co Ltd's Interest Income Expense amounts to -12.1m CNY.
What is Guizhou Xinbang Pharmaceutical Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-1%
The average annual Interest Income Expense growth rates for Guizhou Xinbang Pharmaceutical Co Ltd have been 54% over the past three years , 37% over the past five years , and -1% over the past ten years .